Thursday, June 06, 2024

Breaking Gold Stock News: Getchell Gold Corp.'s (CSE: $GTCH.CN) (OTCQB: $GGLDF) 2024 Field Work Delivers a 7% Increase in the Bulk Density of the Mineralized Host Rock at the Fondaway Canyon Gold Project, Nevada; @getchell_gold

Breaking Gold Stock News: Getchell Gold Corp.'s (CSE: $GTCH.CN) (OTCQB: $GGLDF) 2024 Field Work Delivers a 7% Increase in the Bulk Density of the Mineralized Host Rock at the Fondaway Canyon Gold Project, Nevada; @getchell_gold

 


VANCOUVER, BC - June 6, 2024 (Investorideas.com Newswire) Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce the completion of the bulk density ("BD") field program that forms part of an updated Mineral Resource Estimate ("Updated MRE") at the Fondaway Canyon gold project in Nevada.

 

Key Highlights

  • 7% Increase to the density of the mineralized host rock;
  • Bulk density is one of the main factors utilized in mineral resource estimates;
  • The Updated MRE for the Fondaway Canyon gold project is in progress; and
  • 8 drill holes with notable gold intervals, not previously incorporated, will augment the Updated MRE;

 

Bulk Density Program

The Company published its first Mineral Resource Estimate* ("2023 MRE") for the Fondaway Canyon gold project (Company news release dated February 1, 2023), reporting:

  • Inferred Mineral Resource of 38.3 million tonnes at an average grade of 1.23 g/t Au for
    1,509,100 ounces of gold; and
  • Indicated Mineral Resource of 11.0 million tonnes at an average grade of 1.56 g/t Au for an additional 550,800 ounces of gold;

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Getchell Gold Corp.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/news/2024/06061GTCH-Fondaway-Canyon-Gold-Project.asp

As there was an insufficient population of bulk density samples previously collected, a default density of 2.56 g/cm3 was assigned to the rock hosting the mineralized zones in the 2023 MRE. In order to establish a more representative value to be utilized in the Updated MRE, a field program was initiated in April 2024 to measure a statistically significant population of drill core.

 

A total of 1,382 sample measurements were recorded from nine holes drilled by the Company between 2020 and 2022, well representative of the lithologies, alteration, and mineralization contained within the mineral resource. Validating the field measurements, a subset of 121 samples was sent to Bureau Veritas analytical laboratory in Sparks, Nevada for independent confirmation and to provide a number of measurements using a wax coating methodology.

 

A density of 2.74 g/cm3, representing a 7% increase, was derived from the BD program and assigned to the rock hosting the mineralized zones. This value is a direct input factor in a mineral resource estimate and may potentially represent a commensurate increase in tonnes given all other factors and inputs remain unchanged.

 

"The positive result of the bulk density sampling program is another one in a long series of positive results produced by Getchell Gold Corp. at Fondaway Canyon, and one that continues to increase the attractiveness and potential of the project." states Mike Sieb, President of the Company.

 

Updated Mineral Resource Estimate

Of the 26 holes drilled by the Company in the Central Area of Fondaway Canyon since 2020, only 18 of those holes were incorporated into the 2023 MRE. The results of the additional eight (8) drill holes were received after the cutoff date for data to be included in the 2023 MRE. All eight (8) of these drill holes, FCG22-20 to FCG22-28, excluding FCG22-24 that drilled a separate target area, reported significant intervals of gold mineralization**:

 



Figure 1: Fondaway Canyon Gold Project – Drill Hole Location Plan Map of holes not included in the MRE (CNW Group/Getchell Gold Corp.)




Mike Dufresne, P.Geo., of Apex Geoscience Ltd., is the Qualified Person (as defined in National Instrument 43-101) who reviewed and approved the content and scientific and technical information in the news release.

 

** Drill results published in Company news releases dated November 2 and 15, 2022, and January 10 and 18, 2023.

 

*Notes on the 2023 Mineral Resource Estimate:

 

1. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. There has been insufficient exploration to define the Inferred Resource as Indicated or Measured Mineral Resources, however, it is reasonable to expect that the majority of the Inferred Mineral Resource could be upgraded to Indicated Mineral Resources with continued exploration. There is no guarantee that any part of the mineral resources discussed herein will be converted into a mineral reserve in the future. The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, marketing, or other relevant issues. The Mineral Resources in this report were estimated using the Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") standards on mineral resources and reserves, definitions, and guidelines prepared by the CIM standing committee on reserve definitions and adopted by the CIM council (CIM 2014 and 2019).

 

2. The effective date of the Mineral Resource Estimate is December 15, 2022, and a technical report on the Fondaway Canyon project titled "Technical Report Mineral Resource Estimate Fondaway Canyon Project, Nevada, USA" was filed by the Company on SEDAR+ on February 1, 2023.

 

3. The independent and qualified person for the MRE, as defined by National Instrument 43-101, is Michael Dufresne, P.Geo., from APEX Geoscience Ltd.

 

4. The Mineral Resource Estimate is underpinned by data from 518 reverse circulation and diamond drillholes totalling 52,395m of drilling that intersected the mineralized domains.

 

5. The mineral resource is reported at a lower cut-off of 0.3 g/t Au for the conceptual open pit and 2.0 g/t Au for the conceptual underground extraction scenario. The lower cut-off grades and potential mining scenarios were calculated using the following parameters: mining cost = US$2.70/t (open pit); G&A = US$2.00/t; processing cost = US$15.00/t; recoveries = 92%, gold price = US$1,650.00/oz; royalties = 1%; and minimum mining widths = 1.5 metres (underground) in order to meet the requirement that the reported Mineral Resources show "reasonable prospects for eventual economic extraction".

 

6. Original Au assays were composited to 1.5 m with 11,957 composites generated overall in the mineralized domains including 9,980 composites generated for the Central Zone, 1,323 for the Mid-Realm / South Mouth Zone, and 654 for the Silica Ridge / Hamburger Hill Zone.

 

7. Grade interpolation was performed by ordinary kriging using 1.5 metre composites (block size of 3m x 3m x 3m).

 

8. A default density of 2.56 g/cm3 was used for the mineralized zones.

 

9. The mineral resources estimate is categorized as indicated or inferred and classified based on data density, data quality, confidence in the geological interpretation and confidence in the robustness of the grade interpolation. The indicated category was defined by a search ellipse extending 55m along the major axis, 40m along the minor axis, and 10m vertical. In addition, a minimum of 3 drill holes were required, reporting 9 samples with a maximum of 3 samples per drill hole. The inferred category was defined using a search of up to 120 m and requiring at least 1 sample per drillhole from a minimum of 2 drillholes.

 

10. High-grade capping supported by statistical analysis was completed on composite data for each zone and was established at 29 g/t Au for the Central Zone, 6.5 g/t Au for the Mid Realm - South Mouth Zone, and 8.0 g/t Au for the Silica Ridge – Hamburger Hill Zone.

 

11. The number of metric tonnes was rounded to the nearest thousand and gold ounces was rounded to the nearest hundred, and any discrepancies in the totals are due to rounding effects. Metal content is presented in troy ounces (tonnes x grade (g/T) / 31.10348).

 

12. The author is not aware of any known environmental, permitting, legal, title-related, taxation, socio-political or marketing issues or any other relevant issue not reported in the technical report that could materially affect the mineral resource estimate.

 

About Getchell Gold Corp.

The Company is a Nevada focused gold and copper exploration company trading on the CSE: GTCH, OTCQB: GGLDF, and FWB: GGA1. Getchell Gold is primarily directing its efforts on its most advanced stage, 100% owned, Fondaway Canyon gold project, a past gold producer with a large mineral resource estimate. Complementing Getchell's asset portfolio are the 100% owned; Dixie Comstock, a past gold producer with a historic resource and two earlier stage exploration projects, Star (Cu-Au-Ag), and Hot Springs Peak (Au) projects. Fondaway Canyon and Dixie Comstock properties are located in Churchill County, Nevada.

For further information please visit the Company's website at www.getchellgold.com or contact the Company at info@getchellgold.com.

 

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

 

Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the timing and results, albeit an increase or decrease, of the specific density characterization program or of an updated Mineral Resource Estimate at the Fondaway Canyon gold project; and the launching and completion of the Financing, the terms of the Financing, the issuance and vesting of Warrants, payment of finder's fees in connection with the Financing, receipt of all applicable regulatory approval of the Financing, and the use of proceeds. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of Getchell have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

 

SOURCE Getchell Gold Corp.

 

Getchell Gold (CSE:GTCH.CN;OTCQB:GGLDF) is a featured mining stock on Investorideas.com

 

More info on Getchell at Investorideas.com Visit: https://www.investorideas.com/CO/GTCH/

 

Get News Alerts on Getchell Gold

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure: Getchell Gold Corp. is a paid featured mining stock on Investor ideas. Read full disclosure https://www.investorideas.com/About/News/Clientspecifics.asp




Mining Sector Stocks- investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory  


Get News Alerts on Mining Stocks

 

 

Breaking Mining Stock News: New Destiny (TSXV: $NED.V) Welcomes Lubica Parilakova as Investor Relations; @NEDminingcorp

 

Breaking Mining Stock News: New Destiny (TSXV: $NED.V) Welcomes  Lubica Parilakova as Investor Relations; @NEDminingcorp

 


 

Vancouver, British Columbia – June 6, 2024 – (Investorideas.com Newswire) New Destiny Mining Corp. (TSXV: NED), (the “Company” or “NED) is pleased to announce the appointment of Lubica Parilakova as the new Investor Relations Lead. Lubica brings with her a wealth of experience in the investor relations sector, honed over more than a decade in the mining industry.  Lubica is a seasoned professional with a proven track record of building and managing investor relations programs that enhance investor confidence and maximize shareholder value. Her expertise spans developing comprehensive investor relations strategies, managing investor communications, and fostering relationships with key stakeholders.  With a career that started in the mining industry in 2011, Ms. Parilakova has demonstrated her ability to drive investor engagement and market outreach through her work with junior resource companies. Her multifaceted skills in finance, investments, geology, and mining, paired with her creative approach to investor relations, make her a perfect fit for New Destiny Mining Corp.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of New Destiny Mining

 

Read this news, featuring NED in full at https://www.investorideas.com/news/2024/06061NED-Lubica-Parilakovaas.asp

 

 

"We are excited to welcome Lubica to our team," said Barry Brown, Director of New Destiny Mining Corp. "Her extensive experience and proven success in the mining industry will be invaluable as we continue to grow and strengthen our relationships with the investment community. We look forward to her contributions to enhancing our corporate communications and expanding our investor base."

 

 


 

 

 

Ms. Parilakova, an arm’s length provider, will be responsible for developing and executing New Destiny Mining Corp.'s investor relations strategies, managing communications with investors, and working closely with the executive team to ensure timely and accurate dissemination of information. The initial term of the investor relations agreement will be for 12 months. Ms. Parilakova does not currently own shares in New Destiny Mining. The agreement is subject to the approval of the TSX Venture Exchange.

 

ON BEHALF OF THE BOARD OF DIRECTORS

“Barry Brown”

Director

 

For further information, please contact: Barry Brown, Director

Email: office@newdestinymining.com

Phone: (604) 488-3900.

Website: www.newdestinymining.com

 

 


About New Destiny Mining Corp. New Destiny Mining Corp. is a Canadian-based mineral exploration company focused on the discovery and development of mineral resources. The Company's flagship project, the Treasure Mountain Silver Property, is located in southern British Columbia. New Destiny Mining Corp. is committed to creating value for its shareholders through the exploration and development of high-quality mineral assets.

 

Forward Looking Information

This press release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

NEW DESTINY MINING CORP. TSX-V: NED

888 Dunsmuir Street, Suite 888 Vancouver, BC V6C 3K4


New Destiny Mining Corp. (TSXV: NED) is a featured mining stock on Investorideas.com

 

More info on NED at Investorideas.com Visit: https://www.investorideas.com/CO/NED/

 

Disclaimer/Disclosure: New Destiny Mining Corp. (NED.V) is a paid featured mining stock on Investor Ideas. More info:Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

 

 

 

Wednesday, June 05, 2024

Breaking Mining News: Alaska Energy Metals (TSXV: $AEMC) (OTCQB: $AKEMF) Closes Option to Acquire the Bambino Nickel - Copper Property and Commences Exploration Programs on Its Quebec Properties; @AKEnergyMetals

Breaking Mining News: Alaska Energy Metals (TSXV: $AEMC) (OTCQB: $AKEMF) Closes Option to Acquire the Bambino Nickel - Copper Property and Commences Exploration Programs on Its Quebec Properties; @AKEnergyMetals

 


VANCOUVER, British Columbia - June 5, 2024 (Investorideas.com Newswire) Alaska Energy Metals Corporation (TSX-V: AEMCOTCQB: AKEMF) ("AEMC" or the "Company") is pleased to announce the TSX Venture Exchange has accepted the transaction announced on May 22, 2024. The Company has entered into an agreement (the "Option Agreement"), pursuant to which it will be granted an option to acquire a 100% interest in the 57-claim, 3,320-hectare Bambino nickel - copper platinum group element property located in the Temiscaming Region of western Quebec. Under the terms of the Option Agreement the Company has issued 150,000 common shares to the vendors. The shares are subject to a hold period and may not be traded before October 4, 2024.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Alaska Energy Metals

 

Read this news featuring AEMC in full at https://www.investorideas.com/news/2024/06051AEMC-Closes-Option-to-Acquire-Bambino-Nickel.asp

 

For additional information, visit: https://alaskaenergymetals.com/

 

ABOUT ALASKA ENERGY METALS
Alaska Energy Metals Corporation (AEMC) is an Alaska-based corporation with offices in Anchorage and Vancouver working to sustainably deliver the critical materials needed for national security and a bright energy future, while generating superior returns for shareholders.

 

AEMC is focused on delineating and developing the large-scale, bulk tonnage, polymetallic Eureka deposit containing nickel, copper, cobalt, chromium, iron, platinum, palladium, and gold. Located in Interior Alaska near existing transportation and power infrastructure, its flagship project, Nikolai, is well-situated to become a significant domestic source of strategic energy-related metals for North America. AEMC also holds a secondary project, 'Angliers-Belleterre,' in western Quebec and the Bambino property, which is adjacent to the Angliers claim block. Today, material sourcing demands excellence in environmental performance, carbon mitigation, and the responsible management of human and financial capital. AEMC works every day to earn and maintain the respect and confidence of the public and believes that ESG performance is measured by action and led from the top.

 

ON BEHALF OF THE BOARD
"Gregory Beischer"
Gregory Beischer, President & CEO

 

FOR FURTHER INFORMATION, PLEASE CONTACT:
Gregory A. Beischer, President & CEO
Toll-Free: 877-217-8978 | Local: 604-638-3164

 

Sarah Mawji, Public Relations
Final Edit Media and Public Relations
Email: sarah@finaleditpr.com

 

Some statements in this news release may contain forward-looking information (within the meaning of Canadian securities legislation), including, without limitation, that it will drill holes to test the Canwell, Odie and Emerick prospects and do more geophysical surveys in 2024. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the statements. Forward-looking statements speak only as of the date those statements are made. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable law, the Company assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions, or changes in other factors affecting the forward-looking statements. If the Company updates any forward-looking statement(s), no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 

Alaska Energy Metals Corporation (TSXV: AEMC) (OTCQB: AKEMF) (FRA: V7F) is a featured mining stock on Investorideas.com

 

More info on AEMC at Investorideas.com Visit: https://www.investorideas.com/CO/AEMC/

 

Get News Alerts on Alaska Metals

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. Disclosure: Alaska Energy Metals is a paid featured mining stock on Investorideas.com effective January 5, 2023, More info https://www.investorideas.com/About/News/Clientspecifics.asp

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/




Mining Sector Stocks- investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory 



 Get News Alerts on Mining Stocks

 

 

Tuesday, June 04, 2024

Medical Device Stocks Setting New Standards (NASDAQ: $AEMD) (NASDAQ: $CTSO) (NASDAQ: $CERS) (NYSE: $BAX) (TSX: $EDT.TO) @CytoSorbents @SpectralMedical @baxter_intl

Medical Device Stocks Setting New Standards (NASDAQ: $AEMD) (NASDAQ: $CTSO) (NASDAQ: $CERS) (NYSE: $BAX) (TSX: $EDT.TO) @CytoSorbents @SpectralMedical @baxter_intl

 

June 4, 2024 - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

According to Straits Research ”The global blood purification equipment market size was valued at USD 17,755.6 million in 2021. It is expected to reach USD 29242.21 million by 2030.”

 

Aethlon Medical, Inc. (Nasdaq: AEMD), with a long history of development for its patented Hemopurifier® blood purification device, just released an update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical

 

Read this article, featuring AEMD in full at  https://www.investorideas.com/news/2024/biotech/06041Medical-Device-Stocks.asp

 

"We continue to make progress preparing for our planned, safety, feasibility and “dose finding” oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update”, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. “In early May, we announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of our Hemopurifier®. This data has been quickly integrated into the required documentation for Ethics Committees at our potential clinical sites. On May 17, 2024, we provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board.  An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees.”

 

“Once we receive the expected Ethics Committee approvals, we will finalize the Clinical Trial Agreements. After this, hospitals can begin recruiting patients for the trials.”

 

As a reminder, the target patient population for these safety, feasibility, and dose finding trials is oncology patients with solid tumors who are failing their anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

 

Zach’s Research recently commented on Aethlon following positive data from an in vitro binding study it had implemented of the potential for the Hemopurifier® to remove extracellular vesicles (EVs) directly from plasma of cancer patients.

 

“The data from this in vitro study is a critical element enabling the company to move the Hemopurifier forward in clinical oncology studies towards potential regulatory approval and commercialization. The company next intends to add this data to its Clinical Investigator Brochure, which will then be submitted to the Ethics Committees at clinical sites that are interested in participating in the planned phase 1 oncology trials in Australia and India. We expect AEMD to submit the Clinical Investigator Brochure this month.”

 

“AEMD will then seek to obtain approval by the respective Ethics Boards of interested sites in India. The company has a strong clinical working relationship with Medanta Medicity Hospital in Delhi, India, which is currently participating in a study of the Hemopurifier in COVID patients and it would not surprise us if Medanta Medicity Hospital had interest in participating in the oncology study.”

 

“Depending on how long it takes for the sites to review and potentially approve moving forward to participate in Aethlon’s phase 1 trial, we believe clinical efforts could begin in 2H24. If Aethlon can demonstrate the ability of the Hemopurifier to improve outcomes of cancer patients suffering from a variety of different cancer types, we would anticipate strong commercial prospects for the Hemopurifier.”

 

In early May, CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, announced unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and a sequential quarterly increase of 22%.

 

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce a strong start to 2024, driven by significant sales growth and operational efficiencies. First quarter 2024 product sales were $9.0 million, marking the highest quarter for core CytoSorb sales in nearly 3 years. We expanded our product gross margins to 76%, exclusive of a non-recurring inventory adjustment, up an absolute 8% from Q1 2023, which we believe highlights the scalability and efficiency of our state-of-the-art manufacturing facility and processes.”

 

Furthermore, Principal Investigator Dr. Michael Mack presented the results of the U.S. and Canada pivotal STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) randomized controlled trial at the Annual Meeting of the American Association for Thoracic Surgery (AATS) and at the KOL and Investor/Analyst Day we hosted earlier this week (replay available) that we believe support a favorable benefit-to-risk profile of the DrugSorb-ATR system* in the perioperative bleeding risk of patients undergoing isolated coronary artery bypass graft (CABG) surgery within 2 days of receiving Brilinta® (ticagrelor, AstraZeneca). We received positive and encouraging feedback on the importance of these data and the continued unmet medical need from cardiothoracic surgeons. Looking ahead, we expect to submit marketing applications for DrugSorb-ATR, which has an FDA Breakthrough Device Designation, to the FDA under the De Novo pathway, and Health Canada in the third quarter of 2024.”

 

Also focused on blood purification, Cerus Corporation (Nasdaq: CERS), dedicated solely to safeguarding the world’s blood supply, announced financial results for the first quarter ended March 31, 2024.

 

Highlights included:

 

·        U.S. ReCePI Phase 3 clinical trial successfully met primary endpoint for INTERCEPT Blood System for Red Blood Cells in cardiovascular surgery patients.

 

·        Received FDA approval of extended shelf life for INTERCEPT Platelet Processing Sets to 12 months, doubling the previous shelf life.

 

·        Advanced the LED illuminator program towards the Company’s target commercial launch in the EU in 2025.

 

The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million.

 

"The Cerus team delivered against our plans for Q1, paving the way for the balance of 2024, with great progress on clinical milestones and a strong return to growth for our commercial business. The positive topline readout from ReCePI, the U.S. Phase 3 clinical trial for INTERCEPT Red Blood Cells, is a significant milestone for the program and for our efforts to potentially bring this product to the market globally," stated William "Obi" Greenman, Cerus’ President and Chief executive Officer. "Red blood cells are the most commonly transfused blood components worldwide, and we are committed to providing the full INTERCEPT portfolio for all transfused blood components to our customers around the globe."

 

The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System of Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage.

 

In mid- May, Spectral Medical Inc. (TSX: EDT), a Phase 3 company seeking US FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”), announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. 

 

PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

 

Spectral has continued its significant progress throughout the first quarter of 2024 both clinically and operationally and year-to-date enrolled 25 patients for a total of 106 patients out of the 150 total patient’s target. The Company is focused on the final push to fully enroll and finish the Tigris trial and believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023 could further accelerate enrollment and allow Spectral to rapidly reach the 150-patients target, bringing the Company closer to FDA submission and potential FDA approval. In parallel to its clinical trial, the Company continues to work closely with its commercialization partner, Baxter. In Q1 2024, Baxter exercised its right to maintain its exclusive distribution for PMX products in the U.S. and Canada and paid Spectral a non-dilutive milestone payment. Additionally, Spectral and Baxter mutually agreed to amend the initial term of their commercial partnership to ten years post-FDA approval of PMX. The Company believes this amendment provides a mutually beneficial runway for the parties to maximize PMX commercial economics, while providing motivation for continued support and allocation of resources to the PMX partnership.

 

Blood Purification technology made headlines during the pandemic when several companies including Baxter International Inc. (NYSE:BAX) received emergency use authorization (EUA) from the US FDA. Baxter’s approval was for the company's Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT). 

 

Separate from its current focus on cancer treatment, Aethlon (Nasdaq: AEMD) investigates the potential for the use of the Hemopurifier® in viral diseases under an open Investigational Device Exemption (IDE) and their FDA Breakthrough Designation for “…the treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy.” 

 

Based on our studies to date, the Hemopurifier can potentially clear many viruses that are pathogenic in humans, including HCV, HIV, Sars-CoV-2, and Ebola.”

 

For the companies in this sector, the drive for innovation is ‘in their blood‘, and with the global threats of viruses and future pandemics on the rise, it’s a sector worth watching.

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 


About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com -Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories